Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Although some patients can be cured by current therapies, novel agents are needed to further improve outcomes. We hypothesized that Src tyrosine kinase inhibition by dasatinib may have antilymphoma effects. Here, we demonstrate that dasatinib inhibits cell growth through G 1 -S blockage in five of seven DLBCL cell lines at clinically achievable concentrations. Compared to resting B cells, DLBCL has increased tyrosine phosphorylation activities. As expected, dasatinib inhibits phosphorylation of several Src family kinase members. However, this inhibition occurs in all cell lines regardless of their proliferative response to the drug. In contrast, the activity of two downstream signaling molecules, Syk and phospholipase Cc2 (PLCc2), are well correlated with cell line sensitivity to dasatinib, suggesting that these molecules are crucial in mediating the proliferation of activated lymphoma cells. Furthermore, dasatinib inhibits B-cell receptor signaling in primary lymphoma cells. Together, our findings not only show dasatinib as a potentially useful therapy for DLBCL but also provide insights into the pathogenesis of the lymphoma. The results further suggest the possibility of using Syk and PLCc2 as biomarkers to predict dasatinib therapeutic response in prospective clinical trials.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy. It accounts for approximately 30% of non-Hodgkin lymphomas (NHLs) and over 80% of aggressive lymphomas. 1 The annual incidence of the malignancy in the United States has been rapidly and continuously rising since 1940. 2 DLBCLs are classified primarily based on their diffuse histologic pattern and the morphology of the malignant cells. However, this type of lymphoma represents a heterogeneous group of diseases with a wide range of variability in both clinicopathological features and final outcome. 3 If untreated, this aggressive form of NHL can be fatal within 6 months to 2 years. About 30-40% of patients can be cured using a combined chemotherapeutic regimen of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). Addition of rituximab, an anti-CD20 monoclonal antibody, has significantly improved the cure rate to B60% in large clinical trials, 4, 5 and rituximab in combination with CHOP was recently approved by food and drug administration (FDA) as the first-line treatment for DLBCL. Despite this advance, as well as other limited options, 30-40% of patients still succumb to their disease. Novel agents that specifically target the molecular defects of DLBCL are needed to improve cure rates and to provide therapeutic alternatives to individuals with refractory or recurrent disease.
Aberrantly active B-cell receptor (BCR) signaling has been implicated in the pathogenesis of a number of NHLs including follicular lymphoma, gastric mucosa-associated lymphoid tissue lymphoma and B-cell chronic lymphocytic leukemia. 6, 7 Src family kinases (SFKs) are key mediators in the BCR signal transduction cascade. They are membrane-associated nonreceptor protein tyrosine kinases, including Src, Lyn, Fyn, Hck, Blk, Lck and others. In B cells, following antigen binding to the BCR, the receptor-associated Src kinases, such as Lyn, Fyn and Blk, phosphorylate and activate each other. Activated Src kinases then phosphorylate the cytoplasmic domains of BCR components, resulting in a series of intracellular signaling events that lead to the activation of transcription factors such as nuclear factor-kB, nuclear factor of activated T cells (NFAT) and AP-1. Subsequent expression of their specific transcriptional targets ultimately results in B-cell activation, survival, proliferation, differentiation and/or antibody production. 8 Given their central role in B-cell biology, Src kinases may serve as new therapeutic targets in DLBCL, a possibility that has not yet been explored to date. The involvement of Src kinases in the pathogenesis of DLBCL can be inferred from several recent gene expression profiling studies that aimed to define the molecular heterogeneity underlying its clinical behavioral heterogeneity. In a series of studies, DLBCLs were subclassified into germinal center B-cell type (GCB), activated B-cell type (ABC) and type 3, based on cell-of-origin signatures. [9] [10] [11] In a multiple clustering array analysis, DLBCLs were biologically grouped into Ox-phos, BCR/proliferation and host response signatures. 12 We noted in these independent screening studies that increased BCR signaling is implicated as a common theme in a large number of DLBCLs, as ABC-like lymphomas, as categorized by cell-of-origin signature, resemble in vitro activated B cells, whereas the BCR/proliferation subset, as categorized by the multiple clustering array, exhibits increased expression of genes involved in B-cell activation and proliferation. Our careful examination of the array data revealed that among hundreds of regulated genes in DLBCL, two Src family members, Hck and Blk, are indeed overexpressed at the mRNA level, 12 ,13 supporting our hypothesis that SFK are overly active as part of increased BCR signaling in the tumor cells. SFKs do not stand out as significantly altered in these lymphomas, as the gene microarray technology employed in those studies obviously does not detect dynamic changes in the form of protein phosphorylation. We postulate that pharmacological targeting of Src tyrosine kinases may have antilymphoma activity in DLBCL. To that end, we investigated whether dasatinib, an orally bioavailable inhibitor of all members of SFK, represents an effective strategy to treat DLBCL. Dasatinib, also a potent inhibitor of BCR-ABL, has been recently approved by the FDA for the treatment of imatinib-resistant chronic myeloid leukemia (CML) and Philadelphia chromosomepositive acute lymphocytic leukemia. We used this agent to test our hypothesis and found that dasatinib did inhibit proliferation in five of seven DLBCL cell lines at clinically achievable concentrations. The molecular mechanisms underlying its antilymphoma activity and drug resistance were further investigated, and two potential biomarkers for therapeutic outcome prediction were identified. Our results have provided useful information for prospective clinical trials of dasatinib in relapsed/refractory DLBCL patients and further suggest that targeting the BCR signal transduction pathway represents a new strategy for the treatment of this common and aggressive form of lymphoma.
Materials and methods

Reagents, cell lines, human primary resting B cells and patient samples
Dasatinib (BMS-354825, Sprycel) was obtained from Bristol-Myers Squibb Co. (Princeton, NJ, USA) and was prepared as a 10 mM stock solution in DMSO and stored at À20 1C. Imatinib was purchased from LC laboratories (Woburn, MA, USA), and pyrazolopyrimidine 2 (PP2) was purchased from EMD Chemicals Inc. (Gibbstown, NJ, USA). K562, a BCR-ABLcontaining CML cell line and seven established human DLBCL cell lines, including OCI-LY1 (LY1), -LY3 (LY3), -LY7 (LY7), -LY8 (LY8), -LY10 (LY10), -LY18 (LY18) and VAL, were used in this study. All cell cultures are maintained at 37 1C. K562 cells are grown in RPMI 1640 (Mediatech Inc., Manassas, VA, USA) supplemented with 10% fetal bovine serum (Mediatech Inc., Manassas, VA, USA); LY3 and LY10 cells in Iscove's modified Dulbecco's medium (Hyclone, Logan, UT, USA) with 20% fetal bovine serum; and all the other cell lines in Iscove's modified Dulbecco's medium with 10% fetal bovine serum.
Leukocytes from healthy donors were purchased from the New York Blood Center (Long Island City, NY, USA). Primary human B cells were subsequently purified by negative selection using RosetteSep Human B Cell Enrichment Cocktail (StemCell Technologies, Vancouver, Canada) following the manufacturer 0 s instructions. A purity of above 95% as assessed by CD19 staining was routinely obtained with this method. Fresh and frozen primary DLBCL cells were obtained and studied according to an Institutional Review Board protocol.
Cell counts and cell viability determination
Cells were stained with 2 mg/ml propidium iodide as described previously.
14 Events in live cell gate were counted by an FACS Calibur. Ratio of live to total events was calculated as percent viability.
Immunoblot and immunoprecipitation assays
The analyses were conducted as described previously (see Supplementary Information for details). 14 
Cell cycle analysis
Cells were treated with 100 nM Dasatinib or DMSO for 24-72 h. Cell cycle was determined using the FITC BrdU Flow kit (BD Biosciences, San Diego, CA, USA) following the manufacturer's instructions.
Intracellular phosphospecific flow cytometric assays
Intracellular phosphospecific flow cytometric analyses of Syk, B-cell linker protein (BLNK) and phospholipase Cg2 (PLCg2) were performed using reagents from BD BioSciences (San Diego, CA, USA) according to the protocols provided.
More experimental details for assays used in this study are provided in the Supplementary Information.
Results
Cell growth is potently inhibited by dasatinib in five of seven DLBCL cell lines
Rapid cell growth is a characteristic of DLBCL as evidenced by a high proliferation index assessed by Ki-67. 15 This is also supported by microarray data showing that DLBCL, as opposed to follicular lymphoma and chronic lymphocytic leukemia, demonstrate significantly higher expression of cellular proliferation genes. 9 Moreover, among cases of DLBCL, ABC-like subtype, the most aggressive form relative to GCB-like and type 3, expresses the highest levels of genes in the proliferation signature. 10 As increased cell proliferation may be a result of overly active BCR signaling, we tested the effects of SFK inhibition with dasatinib in seven DLBCL cell lines, including OCI-LY1 (LY1), -LY3 (LY3), -LY7 (LY7), -LY8 (LY8), -LY10 (LY10), -LY18 (LY18) and VAL. These cell lines were divided into GCB and non-GCB subtypes according to immunohistochemical staining patterns of CD10, BCL6 and multiple myeloma 1 (MUM1), which have been shown by several independent groups to correlate well with both cell-of-origin signatures by cDNA microarray and patient survival. [16] [17] [18] Cell lines LY1, LY7, LY8, LY18 and VAL were classified as GCB type and LY3 and LY10 as non-GCB type (Table 1) . Consistent with our findings, LY3 and LY10, the two cell lines previously studied by cDNA microarrays, are categorized as ABC-like DLBCLs. 9 Growth of these cell lines was determined in the presence or absence of p128 nM dasatinib. This dose was chosen because it is equivalent to the maximum serum concentration of dasatinib (Figure 1a ). LY3 and LY18 were the two exceptions; they did not appear to be inhibited by dasatinib at 100 nM. For LY10, the cell count after culturing was lower than the initial plating concentration, as these cells also underwent cell death upon exposure to dasatinib (see below). Time course and full dose titrations of dasatinib for cell growth inhibition were performed. The inhibition can be observed by 72 h of culture in most instances. Results of a typical experiment with LY10 are shown in Figure 1b . IC 50 values of the drug for cell proliferation are summarized in Table 1 . Among the seven cell lines, LY7, LY8, LY10 and VAL demonstrated significant sensitivity to dasatinib with IC 50 below 30 nM. LY1 had intermediate sensitivity with IC 50 B105 nM. In contrast, LY18 was not inhibited until concentrations exceeded 200 nM (IC 50 , 232 nM). The last cell line, LY3, was not inhibited by dasatinib at concentrations as high as 800 nM. Apparently, sensitive and resistant cell lines can belong to either GCB or non-GCB subtypes, suggesting that response does not relate to their molecular subclassifications. Overall, these results demonstrate that dasatinib, at concentrations easily achievable in patients, potently inhibits the proliferation of several DLBCL cell lines.
Specific inhibition of SFK, but not of other tyrosine kinases, is responsible for the growth inhibition of DLBCL
As dasatinib has dual specificity against SRC and ABL, the growth inhibition observed could be a result of either SFK or ABL inhibition. To distinguish between these two possibilities, we tested the effects of imatinib, an ABL/KIT/PDGFRA-selective tyrosine kinase inhibitor, as well as PP2, an SFK inhibitor with a different chemical structure from dasatinib. IC 50 s required for cell growth inhibition by these two inhibitors were compared to dasatinb (Supplementary Table 1 ). As expected, K562 is sensitive to imatinib with an IC 50 of 1.2 mM. All seven DLBCL cell lines are relatively resistant to the drug with an IC 50 close to or greater than 10 mM. In contrast to imatinib, cell lines including K562, LY7, LY8, LY10, VAL and LY1 are inhibited by PP2 with low IC 50 values with respect to typical doses of B10 mM.
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Inhibition of LY18 requires high concentrations of PP2, yet inhibition of LY3 requires even higher concentrations (Supplementary Table 1 ). The sensitivity profile of the DLBCL cell lines to PP2 is, therefore, similar to that of dasatinib but completely different from that of imatinib. These results suggest that the growth inhibition of DLBCL is likely caused by the specific inhibition of SFK but not of other tyrosine kinases.
Cell viability is minimally affected by dasatinib in the majority of DLBCL cell lines
We next determined the effects of dasatinib on the viability of the lymphoma cells. In the K562 cell line, dasatinib effectively killed the BCR-ABL-containing leukemia cells at 0.25 nM (Figure 2a ). However, the DLBCL cell lines showed variable survival response to dasatinib. In LY10, cell death was induced by dasatinib in a dose-and time-dependent manner with an IC 50 for cell killing of B32 nM (Figures 2b and e) . Meanwhile, viability of LY7, LY8 and VAL was only slightly affected ( Figure 2c , showing LY7 only). In contrast, LY1 and LY18 were not influenced by dasatinib treatment (Figure 2d , showing LY1 only). These data showed that, unlike cell growth, the viability of the lymphoma cells is not significantly affected by dasatinib in most of the cell lines.
Lymphoma cells are blocked at G 1 -S phase transition by dasatinib
Having established that cell proliferation is the primary cellular event inhibited by dasatinib in DLBCL cell lines, we then chose a few cell lines to determine the cell cycle stage at which Tyrosine kinase inhibition in DLBCL C Yang et al dasatinib exerts its effect. LY7 was selected to represent sensitive cell lines, and LY18 to represent resistant cell lines. LY10 was also studied as it was the only cell line that showed significant cell death upon dasatinib treatment. Distribution of cells among different cell cycle stages was analyzed following dasatinib treatment ( Figure 3 ). Compared to the untreated cells, a marked reduction in the S phase was observed in LY10 cells at 24 and 48 h following treatment. This was accompanied by a corresponding increase in G 0 /G 1 phase (Figure 3 , LY10, fourth column). A decrease in the S phase with a concomitant increase in G 0 /G 1 was also found in LY7 cells treated with dasatinib. In contrast, the distribution of cells among cell cycle stages was unchanged in LY18 cells. These data are consistent with the proliferative response of these cell lines to dasatinib ( Figure 1 and Table 1 ). Moreover, the results indicate that dasatinib induces G 1 arrest in sensitive lymphoma cells.
Effects of dasatinib on cell cycle regulatory proteins and apoptotic factors
We next studied which cell cycle regulatory proteins were affected by dasatinib. The levels of several cell cycle regulators were examined by immunoblots in lymphoma cell lines. K562 was used as a positive control as a number of cell cycle proteins were downregulated by dasatinib in this BCR-ABL-containing cell line. 22 Downregulation of c-Myc, cyclin-dependent kinase 2 (CDK2), CDK4, CDK6, cyclin D2, cyclin D3, CDK3 and CDK8 was detected in LY10 cells after 72 h of dasatinib treatment (Figure 4, LY10) . However, this downregulation was not detected in LY7, LY18 and LY3 cells (Figure 4 and see discussion). Phosphorylation of CDKs in the CDK/cyclin complexes by CDK-activating kinase contributes to their activation. It is possible that dasatinib affects CDK phosphorylation rather than their expression. Immunoblot analysis showed that phosphorylation of CDK2 was only slightly reduced by dasatinib in LY10 cells, possibly as a result of reduction in the amount of total CDK2. Phosphorylation of CDK2 was largely unchanged in the other DLBCL cell lines (Supplementary Figure 1a) .
It has been shown previously that overexpression of antiapoptotic proteins BCL2 and X-linked inhibitor of apoptosis are associated with poor response to chemotherapy and unfavorable clinical outcome in DLBCL patients. 23, 24 The BCL2-IGH translocation is present in LY10 cells (CY and YLW, data not shown). Downregulation of BCL2 may, therefore, account for the cell death induced by dasatinib in LY10 cells. However, no change in BCL2 levels was detected in LY10, LY18 and LY3 after treatment, whereas little BCL2 was expressed in LY7 (Supplementary Figure 1b) . In contrast to BCL2, a significant reduction in X-linked inhibitor of apoptosis was observed in LY10, but not in the other three cell lines where no cell death occurred upon dasatinib exposure. X-linked inhibitor of apoptosis potently inhibits apoptosis induced by biological agents including Fas ligand, tumor necrosis factor and TNF-related apoptosis inducing ligand (TRAIL), as well as by pharmacological agents including etoposide and paclitaxel. 25, 26 These data together suggest that the extrinsic apoptotic pathway is likely involved in dasatinib-induced LY10 cell death.
Dasatinib inhibits total and SFK tyrosine phosphorylation in DLBCL cell lines
Several microarray studies have shown from the gene expression perspective that B-cell activation and proliferation is a common feature of a significant number of DLBCLs. However, the functional status of tyrosine kinases that relay BCR signals has never been examined in this type of lymphoma. We found that the levels of total tyrosine phosphorylation (pY99), particularly the two bands between 55 and 72 kD, were much higher in We then determined whether dasatinib acts through inhibition of tyrosine phosphorylation in lymphoma cells. As shown in Figure 5c , total tyrosine phosphorylation was significantly suppressed by dasatinib in all three lymphoma cell lines tested (LY10, LY7 and LY18). Moreover, there is good correlation between the degree of tyrosine phosphorylation inhibition (range: 55-72 kD) and cellular response to dasatinib, as nearly complete inhibition was achieved at 50 nM in the sensitive LY10 and LY7 cells, whereas only partial inhibition was achieved at 50 and 100 nM in the relatively resistant LY18 cells. K562 remained the most sensitive to dasatinib, as it was significantly inhibited at 10 nM, possibly as a result of dual inhibition of both Src and ABL kinases in this cell line.
We next examined the phosphorylation of individual members of the Src kinase family in search of the specific member that allows distinction between sensitivity and resistance. Activation of Src, marked by phosphorylation at Y416, was strongly inhibited by 50 nM dasatinib in all four cell lines, including the resistant cell lines LY18 and LY3 (Figure 5d ). Additional analysis showed that phosphorylation of Lyn at Y396 and Hck at Y411 was similarly inhibited in all four cell lines as well. Additionally, immunoprecipitation analysis demonstrated that tyrosine phosphorylation of B lymphoid tyrosine kinase (Blk) was also inhibited by dasatinib in LY10 and LY7 as well as LY18 lymphoma cell lines (Figure 5e ). K562, a cell line of myeloid lineage, does not express Blk. Taken together, we found that members of SFK are similarly inhibited in sensitive and resistant cell lines. These results suggest that inhibition of Src kinases per se may not be sufficient for dasatinib to exert its antiproliferative activity.
Phosphorylation of Syk and PLCg2 but not BLNK predicts the dasatinib response of DLBCL cell lines
One possibility for the lack of correlation between SFK inhibition and the antiproliferative activity of dasatinib is that downstream signaling molecules in the resistant cell lines are not subject to the control of Src kinases. Spleen tyrosine kinase (Syk) is a tyrosine kinase that is phosphorylated and activated by Src kinases following BCR ligation. Activation of Syk subsequently phosphorylates BLNK, an adaptor protein that serves as a docking site for several downstream proteins, including phospholipase Cg2 (PLCg2). Phosphorylation of PLCg2 activates its enzymatic activity, which hydrolyzes phosphatidylinositol-4,5-biphosphate to diacylglycerol and inositol 1,4,5-triphosphate (IP 3 ). These messengers subsequently activate protein kinase C and mobilize calcium, events that ultimately lead to B-cell proliferation. 8 We examined the phosphorylation of Syk, BLNK and PLCg2 in all seven DLBCL cell lines with a highly sensitive intracellular phosphospecific flow cytometric method. In normal B cells, BCR stimulation caused an increase in the levels of p-Syk and p-PLCg2 (Figure 6a , first and second columns, thick-outlined vs dark-shaded peaks). In stimulated B cells, dasatinib treatment led to a decrease in both p-Syk and p-PLCg2, suggesting that both the drug and the assays perform as described previously 27 ( Figure 6a , third and fourth columns, light-shaded vs thickoutlined peaks).
We then examined the DLBCL cell lines. Upon BCR ligation, all cell lines responded by increasing levels of p-Syk and p-PLCg2 (Figures 6b and c, Tyrosine kinase inhibition in DLBCL C Yang et al only one among the seven that responded to dasatinib with a significant amount of cell death. B-cell linker protein (BLNK) was also phosphorylated upon BCR ligation. However, following dasatinib treatment, the direction of changes in p-BLNK did not correlate with drug response. In some cell lines (LY1, LY3 LY18 and VAL), phosphorylation of BLNK even increased upon dasatinib exposure (CY and YLW, data not shown). Collectively, these data suggest that inhibition of Syk and PLCg2, but not BLNK, are the key molecular events that mediate the antiproliferative activity of dasatinib.
BCR signaling in primary DLBCL is inhibited by dasatinib
We next determined whether BCR signaling in primary DLBCL cells is also affected by dasatinib. Immunoblots demonstrated that the phosphorylation of SFK members, including p-Src, p-Lyn and p-Hck, was strongly inhibited by dasatinib (Figure 7a ). Phosphorylation of Syk and PLCg2 was also inhibited to a varying degree in the three primary cases examined ( Figure 7b ). As in the lymphoma cell lines, stimulation of BCR in primary DLBCL cells caused increases in the levels of p-Syk and p-PLCg2 (Figure 7b , first and second columns, thick-outlined vs dark-shaded peaks). Moreover, this increase was inhibited in all three cases by dasatinib treatment as shown by left-shifts of the phosphor peaks (Figure 7b , third and fourth columns, light-shaded vs thickoutlined peaks). Ex vivo lymphoma cells underwent spontaneous apoptosis, and dasatinib did not significantly affect this process in three cases tested (Supplementary Figure 2) . This result is not surprising because the tyrosine kinase inhibitor mainly affects cell proliferation. Taken together, our data provide clear evidence that BCR signaling is inhibited by dasatinib not only in cell lines but also in primary DLBCL cells.
Discussion
Despite recent advances in the treatment of DLBCL, it remains an incurable disease for a significant number of patients. New therapies that specifically target the molecular defects in the lymphoma cells are therefore of potential value. We hypothesized that SFK targeting represents a potentially useful strategy to treat DLBCL based on the fact that (1) SFKs are essential relays in the B-cell signaling cascade leading to B-cell activation and proliferation and (2) BCR activation and B-cell proliferation are central features of DLBCL. Dasatinib, a novel, orally active and clinically available Src tyrosine kinase inhibitor that was recently approved for the treatment of CML, was used to test our hypothesis.
We found that dasatinib potently inhibited the proliferation of five of seven DLBCL cell lines at low, clinically achievable concentrations. The agent has been tested in several other solid or hematological tumors. [28] [29] [30] [31] [32] However, the concentrations used in some of the studies were much higher than those used clinically in CML patients. 28, 32 The use of high concentrations raises the concern of drug toxicity, as pleural effusion is a welldocumented side effect of dasatinib. 33 In the current study, we define sensitivity as IC 50 less than 128 nM. Using this criterion, five cell lines including LY1, LY7, LY8, LY10 and VAL are considered sensitive. LY3 is a resistant cell line, whereas LY18 is considered relatively resistant with an IC 50 of 230 nM. Given the clinical and molecular heterogeneity of DLBCL, it is not surprising that two of the cell lines do not respond well to dasatinib. Subclassification of lymphoma cell lines by cell-oforigin signatures did not appear to correlate with drug sensitivity. Specific inhibition of SFK, but not of other tyrosine kinases, was shown to be responsible for the cellular inhibitory response.
Inhibition in sensitive lymphoma lines was achieved mainly through the suppression of cell proliferation as opposed to induction of cell death. Further analysis revealed that the suppression of cell proliferation was caused by cell cycle arrest at the G 1 -S-phase transition. This effect was more prominent in LY10 but less prominent in LY7 cell lines. Immunoblots of cell cycle regulatory proteins revealed reduced expression of c-Myc, CDK2, CDK4, CDK6, cyclin D2, cyclin D3, CDK3 and CDK8 in dasatinib-treated LY10 cells but no detectable changes in LY7 cells, suggesting that either immunoblots were not sensitive Tyrosine kinase inhibition in DLBCL C Yang et al enough to detect the subtle changes in LY7 or that other mechanisms might be responsible for the drug response in this particular cell line. For the two resistant cell lines, the results are as expected. In LY18, dasatinib treatment (100 nM) did not change the distribution of cells in different phases of the cell cycle. Additionally, none of the cell cycle regulatory molecules was affected by dasatinib in LY18 and LY3. The finding that LY10 responds to dasatinib is encouraging. The cell line is known as an ABC-like DLBCL, and patients with this subtype have a less favorable prognosis due to poor response to CHOPbased therapy. 9 Our data suggest the possibility that patients resistant to conventional therapies may respond to therapies based on tyrosine kinase inhibition.
Our results demonstrate for the first time that there was a higher level of tyrosine phosphorylation in DLBCL cells than in resting B cells from normal individuals. This property may render lymphoma cells more susceptible to inhibition than normal B cells. As expected, the drug inhibits the activation of SFK including Src, Lyn, Hck and Blk. The inhibition occurred in the presence or absence of BCR ligation (CY and YLW, data not shown). Somewhat unexpectedly, inhibition of SFK phosphorylation occurred invariably in all seven cell lines regardless of their proliferative response to dasatinib, suggesting that inhibition of SFK per se is insufficient to produce effects on cell growth.
Further analyses of the downstream transducers, Syk and PLCg2, revealed a completely different phosphorylation response. Importantly, these response patterns allow us to distinguish drug sensitivity from resistance. In stimulated lymphoma cells, dasatinib caused considerable reduction in the phosphorylation of Syk and PLCg2 in sensitive cell lines including LY1, LY7, LY8 and VAL. In contrast, no significant Tyrosine kinase inhibition in DLBCL C Yang et al reduction occurred in LY3 and LY18, suggesting that SFKindependent activation of Syk and PLCg2 exists in these two resistant cell lines (see schematic models in Figure 8 ). These results highlight the crucial roles of Syk and PLCg2 in the pathogenesis of DLBCL, as inhibition of their key activities leads to eventual cell cycle arrest in sensitive cell lines, whereas inability to do so results in continued cell growth despite reduced activities of the upstream SFK. Among the cell lines tested, LY10 was the only exception to this rule. However, its response to dasatinib can be defined by apoptotic assays. Inhibition of Syk by dasatinib is unlikely to be through a direct effect, although Syk is a protein tyrosine kinase by itself. A previous study demonstrated that K D of dasatinib for Syk is 3000 nM. 34 In contrast to Syk and PLCg2, phosphorylation of BLNK changes in different directions in different cell lines. There did not seem to be any correlation between BLNK phosphorylation and proliferative response to the drug among the cell lines. These results suggest that the sequence of events in the lymphoma cells might be different from those in normal B cells. In support of this speculation, Sprangers et al. 35 have found several human lymphoma cell lines that carry mutations in the BLNK gene including deletions, 3 0 truncations, mutations in splice sites and small deletions in tyrosine residue codons. Moreover, BCR signaling can be transmitted by the direct interaction between Lyn and PLCg1, causing calcium mobilization in the absence of BLNK.
Most interestingly, our data identified p-Syk and p-PLCg2 as potential biomarkers to predict patient response to SFK inhibitors. We demonstrated that phosphospecific flow cytometric assays for these signaling molecules perform well in primary lymphoma cells, making it both feasible and practical to apply this technology to patients' primary tumor biopsies. Whether p-Syk and p-PLCg2 can be used as response predictors would need to be prospectively verified through clinical trials, which are currently under development.
In conclusion, we demonstrated that dasatinib induces G 1 arrest in DLBCL through inhibition of the Src-Syk-PLCg2 pathway. Changes in p-Syk and p-PLCg2 upon dasatinib treatment clearly showed distinctive patterns in the sensitive and resistant cell lines. Our studies have laid the foundation for prospective clinical trials in DLBCL patients using FDA approved doses as a starting point and two signaling molecules as potential biomarkers to predict therapeutic outcome. The findings of this study highlight components of the BCR signaling pathway as novel targets in the treatment of DLBCL. Tyrosine kinase inhibition in DLBCL C Yang et al
